Skip to Main Content

Welcome back to my semi-regular column tracking the ups and downs in small-cap biotech. Here, I take a look at Bellus Health (BLU) and OncoSec Medical (ONCS). (Read to the end for quick hits on Northwest Biotherapeutics (NWBO) and Ampio Pharmaceuticals (AMPE).)

As a reminder, I’m taking requests for companies to cover, so reach out to me on Twitter (DMs are open), email, or in the comment section of the column.


Speaking to Roberto Bellini, the CEO of Bellus Health, left me feeling a bit out of sorts. This was not his fault by any means. We had an engaging conversation about Bellus and its interesting (but early) drug for chronic cough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.